Division of Basic Sciences, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave. N., Seattle, WA 98109, USA.
J Virol. 2010 Jan;84(2):1076-88. doi: 10.1128/JVI.02113-09. Epub 2009 Nov 11.
Human 4E10 is one of the broadest-specificity, HIV-1-neutralizing monoclonal antibodies known, recognizing a membrane-proximal linear epitope on gp41. The lipid cross-reactivity of 4E10 has been alternately suggested either to contribute to the apparent rarity of 4E10-like antibody responses in HIV infections, through elimination by B-cell tolerance mechanisms to self-antigens, or to contribute to neutralization potency by virus-specific membrane binding outside of the membrane-proximal external region (MPER). To investigate how 4E10 interacts with membrane and protein components, and whether such interactions contribute to neutralization mechanisms, we introduced two mutations into 4E10 Fv constructs, Trp to Ala at position 100 in the heavy chain [W(H100)A] and Gly to Glu at position 50 in the light chain [G(L50)E], selected to disrupt potential lipid interactions via different mechanisms. Wild-type and mutant Fvs all bound with the same affinity to peptides and monomeric and trimeric gp140s, but the affinities for gp140s were uniformly 10-fold weaker than to peptides. 4E10 Fv binding responses to liposomes in the presence or absence of MPER peptides were weak in absolute terms, consistent with prior observations, and both mutations attenuated interactions even further, as predicted. The W(H100)A mutation reduced neutralization efficiency against four HIV-1 isolates, but the G(L50)E mutation increased potency across the same panel. Electron paramagnetic resonance experiments showed that the W(H100)A mutation, but not the G(L50)E mutation, reduced the ability of 4E10 to extract MPER peptides from membranes. These results show that 4E10 nonspecific membrane binding is separable from neutralization, which is achieved through specific peptide/lipid orientation changes.
人源 4E10 是一种广谱、中和 HIV-1 的单克隆抗体,能够识别 gp41 上一个位于膜近侧的线性表位。4E10 的脂质交叉反应性曾被认为通过 B 细胞耐受机制消除自身抗原,从而有助于 HIV 感染中 4E10 样抗体反应的罕见性,或者通过病毒特异性膜结合在膜近侧外部区域(MPER)之外来促进中和效力。为了研究 4E10 如何与膜和蛋白成分相互作用,以及这种相互作用是否有助于中和机制,我们在 4E10 Fv 构建体中引入了两个突变,即重链第 100 位的色氨酸突变为丙氨酸[W(H100)A]和轻链第 50 位的甘氨酸突变为谷氨酸[G(L50)E],选择通过不同的机制破坏潜在的脂质相互作用。野生型和突变型 Fv 都以相同的亲和力结合肽和单体及三聚体 gp140,但对 gp140 的亲和力比肽弱 10 倍。4E10 Fv 与脂质体的结合反应在存在或不存在 MPER 肽的情况下绝对较弱,与先前的观察结果一致,并且两种突变进一步减弱了相互作用,正如预期的那样。W(H100)A 突变降低了对四种 HIV-1 分离株的中和效率,但 G(L50)E 突变提高了同一组中的效力。电子顺磁共振实验表明,W(H100)A 突变,而不是 G(L50)E 突变,降低了 4E10 从膜中提取 MPER 肽的能力。这些结果表明,4E10 的非特异性膜结合与中和是可分离的,这是通过特定的肽/脂质取向变化实现的。